Fulgent Genetics (FLGT) Cash from Financing Activities (2016 - 2026)

Fulgent Genetics has disclosed Cash from Financing Activities across 11 years of filings, most recently posting -$24.2 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 818.31% year-over-year to -$24.2 million; the TTM figure through Jun 2026 stood at -$70.0 million (down 376.31% YoY), while the FY2025 annual figure was -$14.8 million, down 205.12% from the prior year.
• Cash from Financing Activities came in at -$24.2 million for Q2 2026 at Fulgent Genetics, up from -$44.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of -$327000.0 in Q4 2024 to a low of -$44.8 million in Q1 2026.
• Average Cash from Financing Activities over 5 years is -$11.9 million, with a median of -$3.6 million recorded in 2023.
• Year-over-year, Cash from Financing Activities tumbled 1086.42% in 2022 and soared 98.74% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$29.6 million in 2022, then grew by 12.31% to -$26.0 million in 2023, then soared by 98.74% to -$327000.0 in 2024, then plunged by 63.3% to -$534000.0 in 2025, then slumped by 4436.52% to -$24.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$24.2 million in Q2 2026, -$44.8 million in Q1 2026, and -$534000.0 in Q4 2025.